Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 832-844

  Schmid, Dagmar A ^a   Wichniak, Adam ^a   Uhr, Manfred ^a   Ising, Marcus ^a   Brunner, Hans ^a   Held, Katja ^a   Weikel, Jutta C ^a   Sonntag, Annette ^a   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Depression; Ghrelin; HPA system; Leptin; Mirtazapine; Sleep

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CHLORAL HYDRATE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GHRELIN; GROWTH HORMONE; HORMONE; HYDROCORTISONE; LEPTIN; MELATONIN; MIRTAZAPINE; PRESYNAPTIC RECEPTOR; PROLACTIN; SEROTONIN 2 RECEPTOR;

ADULT; ALPHA RHYTHM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DELTA RHYTHM; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ELECTROENCEPHALOGRAM; ENDOCRINE FUNCTION TEST; ENERGY BALANCE; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HAMILTON SCALE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NIGHT SLEEP; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PSYCHOMETRY; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SLEEP; SLEEP DISORDER; SLOW WAVE SLEEP; THETA RHYTHM; WEIGHT GAIN;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; AREA UNDER CURVE; BODY WEIGHT; CIRCADIAN RHYTHM; DEPRESSION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ENDOCRINE SYSTEM; FEMALE; GROWTH HORMONE; HORMONES; HUMANS; HYDROCORTISONE; IMMUNORADIOMETRIC ASSAY; LEPTIN; MALE; MELATONIN; MIANSERIN; MIDDLE AGED; PEPTIDE HORMONES; PROLACTIN; PSYCHOMETRICS; SLEEP; TIME FACTORS;

EID: 33645030240     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300923     Document Type: Article

References (84)

1. American Sleep Disorders Association (1992). EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15: 173-184.
2. Antonijevic IA, Murck H, Frieboes RM, Horn R, Brabant G, Steiger A (1998). Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 32: 403-410.
3. Antonijevic IA, Steiger A (2003). Depression-like changes of the sleep-EEC during high dose corticosteroid treatment in patients with multiple sclerosis. Psychoneuroendocrinology 28: 401-418.
4. Armitage R (2000). The effects of antidepressants on sleep in patients with depression. Can J Psychiatry Rev Can Psychiatric 45: 803-809.
5. Aslan S, Isik E, Cosar B (2002). The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 25: 677-679.
6. Bates SH, Myers MG (2003). The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol Metab 14: 447-452.
7. Bischoff P, Mahlstedt D, Blanc I, Esch OSA (1998). Quantitative topographical electroencephalographic analysis after intravenous clonidine in healthy male volunteers. Anesth Analg 86: 202-207.
8. Brandenberger G, Luthringer R, Muller G, Gronfier C, Schaltenbrand N, Macher JP et al (1996). 5-HT2 receptors are partially involved in the relationship between renin release and delta relative power. J Endocrinol Invest 19: 556-562.
9. De Boer T (1995). The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10: 19-23.
10. Dijk DJ, Beersma DG, Daan S, Van den Hoofdakker RH (1989). Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 171: 207-218.
11. Dzaja A, Dalal MA, Himmerich H, Uhr M, Pollmächer T, Schuld A (2004). Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. Am J Physiol Endocrinol Metab 286: E963-E967.
12. Ehlers CL, Kupfer DJ (1987). Hypothalamic peptide modulation of EEG sleep in depression: a further application of the S-process hypothesis. Biol Psychiatry 22: 513-517.
13. Emilien G (1990). Effects of clonidine, yohimbine and eserine on the quantified EEG of rats. Arch Int Pharmacodyn Ther 304: 105-124.
14. Fawcett J, Barkin RL (1998). Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51: 267-285.
15. Hamilton M (1960). A rating scale for depression. J Neurol, Neurosurg Psychiatry 23: 56-62.
16. Hauri P, Hawkins DR (1973). Alpha-delta sleep. Electroencephalogr Clin Neurophysiol 34: 233-237.
17. 1-receptor antagonist R121919 improves sleep EEG in patients with depression. J Psychiatr Res 38: 129-136.
18. Heuser I, Yassouridis A, Holsboer F (1994). The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356.
19. Hinze-Selch D, Schuld A, Kraus T, Kuhn M, Uhr M, Pollmächer T (2000). Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 23: 13-19.
20. Holm S (1979). A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65-70.
21. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
22. Holsboer F (2003). High-quality antidepressant discovery by understanding stress hormone physiology. Ann NY Acad Sci 1007: 394-404.
23. Holsboer F, von Bardeleben U, Steiger A (1988). Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man. Neuroendocrinology 48: 32-38.
24. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschöp M (2001). Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 142: 4163-4169.
25. Idzikowski C, Mills FJ, Glennard R (1986). 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 378: 164-168.
26. Kellner M, Yassouridis A, Manz B, Steiger A, Holsboer F, Wiedemann K (1997). Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers - a potential link to low-melatonin syndrome in depression? Neuroendocrinology 16: 339-345.
27. Kerkhofs M, Linkowski P, Mendlewicz J (1989). Effects of intravenous catheter on sleep in healthy men and in depressed patients. Sleep 12: 113-119.
28. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999). Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
29. Kraus T, Haack M, Schuld A, Hinze-Seich D, Koethe D, Pollmächer T (2002). Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35: 220-225.
30. Kraus T, Haack M, Schuld A, Hinze-Seich D, Kuhn M, Uhr M et al (1999). Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156: 312-314.
31. Künzel HE, Steiger A, Held K, Antonijevic IA, Frieboes RM, Murck H (2005). Changes in sleep-electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers. Psychopharmacology 180: 327-332.
32. Laakmann G, Hennig J, Baghai T, Schüle C (2004). Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Ann NY Acad Sci 1032: 279-282.
33. Laakmann G, Schüle C, Baghai T, Waldvogel E (1999). Effects of mirtazapine on growth hormone, prolactin and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 24: 769-784.
34. Linkowski P, Mendlewicz J, Kerkhofs M, Leclercq R, Golstein J, Brasseur M et al (1987). 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab 65: 141-152.
35. Miles A, Philbrick DR (1988). Melatonin and psychiatry. Biol Psychiatry 23: 405-425.
36. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
37. Murashita M, Kusumi I, Inoue T, Takahashi Y, Hosoda H, Kangawa K et al (2005). Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 30: 106-110.
38. 1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology 155: 187-192.
39. Murck H, Nickel T, Künzel H, Antonijevic IA, Schill J, Zobel A et al (2003). State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacology 28: 348-358.
40. Nemeroff CB (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1: 336-342.
41. Nutt DJ (2002). Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 17: S37-S41.
42. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL et al (2001). Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145: R5-R9.
43. Palazidou E, Papadopoulos A, Sitsen A, Stahl S, Checkley S (1989). An alpha 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 97: 115-117.
44. Pickworth WB, Sharpe LG, Gupta VN (1982). Morphine-like effects of clonidine on the EEG, slow wave sleep and behavior in the dog. Eur J Pharmacol 81: 551-557.
45. Pivik RT, Harman K (1995). A reconceptualization of EEG alpha-activity as an index of arousal during sleep - all alpha-activity is not equal. J Sleep Res 4: 131-137.
46. Ramesh V, Kumar VM (1998). The role of alpha-2 receptors in the medial preoptic area in the regulation of sleep-wakefulness and body temperature. Neuroscience 85: 807-817.
47. Ravussin E, Tschöp M, Morales S, Bouchard C, Heiman ML (2001). Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J Clin Endocrinol Metab 86: 5972.
48. Rechtschaffen A, Kales A (1968). A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. US Department of Health, Education & Welfare, Neurological Information Network: Bethesda, MD.
49. Röschke J, Kögel P, Schlösser R, Wagner P, Mann K, Rossbach W et al (1997). Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology 132: 44-49.
50. Rubin RT, Rhodes ME, Czambel RK (2002). Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Res 113: 255-268.
51. Ruigt GSF, Kemp B, Groenhout CM, Kamphuisen HA (1990). Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 38: 551-554.
52. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H et al (1998). Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44: 3-14.
53. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR (1991). Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14: 439-447.
54. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J (2002a). Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 46: 197-201.
55. Schittecatte M, Dumont F, Machowski R, Fontaine E, Cornil C, Mendlewicz J et al (2002b). Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression. Psychiatry Res 109: 1-8.
56. Schmid DA, Held K, Ising M, Uhr M, Weikel JC, Steiger A (2005). Ghrelin stimulates appetite, imagination of food, GH, ACTH and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 30: 1187-1192.
57. Schüle C, Baghai T, Bidlingmaier M, Strasburger C, Laakmann G (2002a). Endocrinological effects of mirtazapine in healthy volunteers. Prog Neuro-Psychopharmacol Biol Psychiatry 26: 1253-1261.
58. Schüle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G (2002b). The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology 163: 95-101.
59. Schüle C, Baghai T, Zwanzger P, Ella R, Eser D, Padberg F et al (2003). Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. Psychopharmacology 166: 271-275.
60. 1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 209: 41-44.
61. Seifritz E, Stahl SM, Gillin JC (1997). Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Res 759: 84-91.
62. Sharp T, Bramwell SR, Hjorth S, Grahame-Smith DG (1989). Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol 98: 989-997.
63. Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A (1996). Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. Depression 4: 1-13.
64. Spitzer RL, Williams JB, Gibbon M (1987). The structured clinical interview for DSM-III-R: SCID. German version: Wittchen HU, Zaudig M, Schramm E, Spengler P, Mombour W. SKID - Strukturiertes Klinisches Inverview für DSM-III-R. Beltz: Weinheim.
65. Staner L, Luthringer R, Macher JP (1999). Effects of antidepressant drugs on sleep EEG in patients with major depression - mechanisms and therapeutic implications. CNS Drugs 11: 49-60.
66. Steiger A (2002). Sleep and the hypothalamo-pituitary-adrenocortical system. Sleep Med Rev 6: 125-138.
67. Steiger A (2003). Sleep and endocrine regulation. Front Biosci 8(The Basic Science of Sleep): 358-376.
68. Steiger A, von Bardeleben U, Guldner J, Lauer C, Rothe B, Holsboer F (1993). The sleep EEG and nocturnal hormonal secretion. Studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 17: 125-137.
69. Steiger A, von Bardeleben U, Herth T, Holsboer F (1989). Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J Affect Disord 16: 189-195.
70. Thase ME (1999). Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60(Suppl 17): 28-31.
71. Togo T, Hasegawa K, Miura S, Hosojima H, Kojima K, Shoji M et al (2004). Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology 172: 230-232.
72. Tschöp M, Smiley DL, Heiman ML (2000). Ghrelin induces adiposity in rodents. Nature 407: 908-913.
73. Van Bemmel AL, Beersma DG, Van den Hoofdakker RH (1995). Changes in EEG power density of non-REM sleep in depressed patients during treatment with trazodone. J Affect Disord 35: 11-19.
74. Van Bemmel AL, Vermeeren MT, Ruigt G, Sennef C (1999). The acute effects of the noradrenaline reuptake inhibitor Org 4428 on EEG sleep in healthy volunteers. Neuropsychobiology 40: 107-114.
75. Van Cauter E, Latta F, Nedeltcheva A, Spiegel K, Leproult R, Vandenbril C et al (2004). Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res 14(Suppl A): S10-S17.
76. Vgontzas AN, Bixler EO, Wittman AM, Zachman K, Lin HM, Vela-Bueno A et al (2001). Middle-aged men show higher sensitivity of sleep to the arousing effects of corticotropin-releasing hormone than young men: clinical implications. J Clin Endocrinol Metab 86: 1489-1495.
77. Vitiello MV, Larsen LH, Moe KE, Borson S, Schwartz RS, Prinz PN (1996). Objective sleep quality of healthy older men and women is differentially disrupted by nighttime periodic blood sampling via indwelling catheter. Sleep 19: 304-311.
78. Winokur A, DeMartinis III NA, McNally DP, Gary EM, Cormier JL, Gary KA (2003). Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 64: 1224-1229.
79. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA (2000). Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 48: 75-78.
80. World Health Organization (1993). Mental and Behavioural Disorders. Diagnostic Criteria for research Tenth revision of the International Classification of Diseases. World Health Organization: Geneva.
81. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG et al (2001a). Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86: 5992-5995.
82. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA et al (2001b). Ghrelin causes hyperphagia and obesity in rats. Diabetes 50: 2540-2547.
83. Yamadera H, Ferber G, Matejcek M, Pokorny R (1985). Electroencephalographic and psychometric assessment of the CNS effects of single doses of guanfacine hydrochloride (Estulic) and clonidine (Catapres). Neuropsychobiology 14: 97-107.
84. Yeh KC, Kwan KC (1978). Comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm 6: 79-98.